Publication | Open Access

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Surgical OncologyHepatologyMedicinePathologyHigh-risk Hepatocellular CarcinomaLiver CancerOncologyRadiation OncologyHepatocellular CarcinomaMolecular OncologyPhase 3